Prognostic value of NT-proBNP in patients with severe COVID-19.
Adult
Aged
Betacoronavirus
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
Coronavirus Infections
/ diagnosis
Female
Hospital Mortality
Humans
Male
Middle Aged
Mortality
Natriuretic Peptide, Brain
/ analysis
Pandemics
Peptide Fragments
/ analysis
Pneumonia, Viral
/ diagnosis
Predictive Value of Tests
Prognosis
Reference Values
Retrospective Studies
Risk Factors
SARS-CoV-2
COVID-19
NT-proBNT
Outcome
SARS-CoV-2
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
11
03
2020
accepted:
02
04
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown. The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records. The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death. NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19. ClinicalTrials, NCT04292964. Registered 03 March 2020.
Sections du résumé
BACKGROUND
BACKGROUND
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.
METHODS
METHODS
The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.
RESULTS
RESULTS
The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.
CONCLUSION
CONCLUSIONS
NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials, NCT04292964. Registered 03 March 2020.
Identifiants
pubmed: 32293449
doi: 10.1186/s12931-020-01352-w
pii: 10.1186/s12931-020-01352-w
pmc: PMC7156898
doi:
Substances chimiques
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Banques de données
ClinicalTrials.gov
['NCT04292964']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
83Subventions
Organisme : National Natural Science Foundation of China
ID : 81570212
Organisme : National Natural Science Foundation of China
ID : 31800976
Organisme : Chongqing Science and Health Joint Medical Research Project
ID : 2018QNXM024
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Zhonghua Shao Shang Za Zhi. 2020 Jun 20;36(6):471-475
pubmed: 32114747
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Clin Chem. 2017 Jan;63(1):351-358
pubmed: 28062628
BMJ. 2020 Feb 18;368:m641
pubmed: 32071063
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mayo Clin Proc Innov Qual Outcomes. 2020 Jan 08;4(1):50-64
pubmed: 32055771
Emerg Med J. 2011 Feb;28(2):122-7
pubmed: 20511643
J Bras Pneumol. 2019 Aug 12;45(4):e20180417
pubmed: 31411279
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E006
pubmed: 32118393
Physiol Rev. 2018 Jan 1;98(1):505-553
pubmed: 29351514
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Eur J Intern Med. 2006 Dec;17(8):536-40
pubmed: 17142170
Respirology. 2018 Mar;23(3):250-259
pubmed: 29325222
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):147-157
pubmed: 32391658
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Circ Res. 2016 Apr 15;118(8):1313-26
pubmed: 27081112
Heart Fail Rev. 2014 Aug;19(4):421-38
pubmed: 24957908
Respirology. 2013 Aug;18(6):889-90
pubmed: 23714366
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042